York Pharma PLC

While Bristol-Myers Squibb has been at the forefront of immuno-oncology, the big pharma has lagged behind competitors in some other therapeutic areas. The New York pharma is aiming to correct that by

Already very active in deal-making for fibrotic disease companies and candidates in the past year, Bristol-Myers Squibb ponied up $150m in upfront cash on Aug. 31 for an option to acquire Promedior In

The FDA has granted a priority review to Pfizer's new drug application (NDA) for palbociclib as a first-line therapy in combination with letrozole as a first-line treatment for postmenopausal women wi

As expected, Pfizer submitted its new drug application (NDA) to the FDA for palbociclib seeking approval of the drug in breast cancer based on Phase II data from the firm's PALOMA-1 trial. Shares of P